September 26, 2024
NutriQuest partners with Modulant Biosciences to develop new treatment for swine diseases
US-based NutriQuest has announced a partnership with Modulant Biosciences to develop a breakthrough technology for controlling Porcine Reproductive and Respiratory Syndrome (PRRSv) and other swine diseases, Farm Journal's Pork reported.
Modulant Biosciences, an Indiana, US biotechnology company, has identified a small molecule capable of combating the PRRSv virus. NutriQuest shared that this collaboration will expedite the development of the drug candidate.
PRRSv, which has affected the US swine herd since the mid-1980s, remains a significant threat to the pork industry. According to a recent analysis from Iowa State University, PRRSv costs the US pork sector around US$1.2 billion annually.
"Our research partnership with NutriQuest will enable us to evaluate the most effective molecule for treating pigs infected with PRRSv and provide the swine industry with a much-needed tool for disease control," said Tom Campi, CEO of Modulant Biosciences, in a statement.
In addition to PRRSv, the partnership aims to advance research into treatments for other swine diseases, including Porcine Epidemic Diarrhea virus (PEDv) and Swine Influenza virus (SIV). There is also potential for applications in poultry and ruminants, according to the release.
"I am excited about this opportunity for NutriQuest on two important levels," said Steve Weiss, CEO of NutriQuest. "This partnership not only tackles critical challenges for producers but also strengthens NutriQuest's capabilities in regulated drug technology development, opening the door to future innovations in this field."
Modulant Biosciences explained that its technology focuses on host cell processes necessary for viral replication or involved in chronic diseases. This approach aims to provide cost-effective therapies for the animal health industry to treat or prevent diseases that are not well-controlled with existing technologies.
- Farm Journal's Pork
